Defiance Next Gen Altered Experience ETF
Limited financial coverage for PSY.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
About the company
This fund is designed to mirror a systematically constructed index. This index evaluates the performance of companies engaged in specific, legally authorized activities, always in adherence to national laws. These activities encompass the fields of medical psychedelics, therapeutic cannabis, cannabis-derived pharmaceuticals, cannabidiol (CBD) derivatives, and ketamine.
- IPO
- 2021
- HQ
- DE, US
Price Chart
- 52W High
- $5.92
- 52W Low
- $5.84
- 50D MA
- $5.90
- 200D MA
- $5.90
- Beta
- 0.00
- Avg Volume
- 0
Get TickerSpark's AI analysis on PSY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 10, 12 | ROBARDS KAREN P | other | 690 |
| Dec 10, 12 | KESTER W CARL | other | 100 |
| Dec 10, 12 | Harris Jerrold B | other | 161 |
| Dec 10, 12 | CAVANAGH RICHARD | other | 100 |
| Dec 10, 12 | GABBAY HENRY | other | 100 |
| Dec 10, 12 | BASSAS STEPHAN | other | 1,000 |
| Dec 5, 12 | KESTER W CARL | sell | 6,196.02 |
| Dec 5, 12 | CAVANAGH RICHARD | sell | 6,489.78 |
| Dec 5, 12 | HUBBARD ROBERT GLENN | sell | 9,682.1 |
| Dec 5, 12 | ROBARDS KAREN P | sell | 5,726.35 |
Our PSY coverage
Recent articles, reports, and earnings notes.
No research on PSY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PSY report →Similar companies
Peers in the same neighborhood.